The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Sarepta Therapeutics Inc. shares valued at $5,963,124 were purchased by Chambers Michael Andrew on Sep 14. At $104.43 per share, Chambers Michael Andrew acquired 57,100 shares. The insider’s holdings grew to 108,178 shares worth approximately $11.91 million following the completion of this transaction.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Also, Chambers Michael Andrew purchased 46,170 shares, netting a total of over 4,999,230 in proceeds. Following the buying of shares at $108.28 each, the insider now holds 51,078 shares.
Before that, Rodino-Klapac Louise had added 3,780 shares to its account. In a trade valued at $299,867, the Head of R&D, CSO bought Sarepta Therapeutics Inc. shares for $79.33 each. Upon closing the transaction, the insider’s holdings increased to 3,780 shares, worth approximately $7.23 million.
Analysts at Needham resumed the stock at ‘”a Buy”‘ outlook in a report released in early January. As of December 09, 2021, Oppenheimer has increased its “Perform” rating to a “an Outperform” for SRPT. Earlier on November 05, 2021, JP Morgan upgraded its rating. Their new recommendation was “an Overweight” for SRPT stock which previously was a “a Neutral”.
Analyzing SRPT’s Price Performance
On Wednesday, Sarepta Therapeutics Inc. [NASDAQ: SRPT] plunged -3.30% to $110.14. The stock’s lowest price that day was $110.07, but it reached a high of $115.40 in the same session. During the last five days, there has been a surge of approximately 2.39%. Over the course of the year, Sarepta Therapeutics Inc. shares have jumped approximately 22.31%. Shares of the company reached a 52-week high of $120.23 on 09/09/22 and a 52-week low of $61.28 on 06/16/22. A 50-day SMA is recorded $102.81, while a 200-day SMA reached $83.34. Nevertheless, trading volume fell to 1.02 million shares from 0.99 million shares the previous day.
Support And Resistance Levels for Sarepta Therapeutics Inc. (SRPT)
According to the 24-hour chart, there is a support level at 108.34, which, if violated, would cause prices to drop to 106.54. In the upper region, resistance lies at 113.67. The next price resistance is at 117.20. RSI (Relative Strength Index) is 51.35 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.96, which suggests the price will decrease in the coming days. Percent R is at 58.73%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Sarepta Therapeutics Inc. (SRPT)?
According to The Vanguard Group, Inc. filings, the company currently owns 8,300,401 shares, which is about 9.48% of the total SRPT shares outstanding. The investor’s shares have appreciated by 101,196 from its previous 13-F filing of 8199205.0 shares. With the completion of the sale transaction, Janus Henderson Investors US LLC’s stake is now worth $789,350,833. BlackRock Fund Advisors acquire a 1.11% interest valued at $422.85 million while Sands Capital Management LLC sold a -1,071,850 stake. A total of 255,000 shares of Sarepta Therapeutics Inc. were sold by Avoro Capital Advisor LLC during the quarter, and 798,511 were bought by Ecor1 Capital LLC. In its current portfolio, Wellington Management Co. LLP holds 2,768,861 shares valued at $302.86 million.